symphoglobulin-d
mAbexperimental
Clinical trial activity
1 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00718692)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Blood group Rh(D) polypeptideINHIBITOR
RHD inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107859 ↗
Also known as
- rozrolimupab
- rozrolimupab
- sym001
- sym001
- sym001
- sym 001
- sym-001
- sym-001
- symphoglobulin-d
- symphoglobulin-d
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00718692 | Phase 2 | Jul 1, 2008 | Katholieke Universiteit Leuven, Klinika Okulistyki, Prof. Dr. I. Chiricuta Institute of Oncology, Swedish Orphan Biovitrum, Symphogen A/S, Universidad Autonoma de Madrid, University of London, Werlhoff Institut Hannover, Germany |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Klinika Okulistyki | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Prof. Dr. I. Chiricuta Institute of Oncology | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Swedish Orphan Biovitrum | For profit | 1 | 0 | 1 | 2008 |
| Symphogen A/S | For profit | 1 | 1 | 1 | 2008 |
| Universidad Autonoma de Madrid | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Werlhoff Institut Hannover, Germany | Academic/Hospital | 1 | 0 | 1 | 2008 |
8 organizations
Page 1 / 1